Endoscopic papillo-sphincterotomy: Prevention of pancreatic reaction by somatostatin

P. Testoni, E. Masci, F. Bagnolo, A. Tittobello

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Acute pancreatitis is widely considered as a harmful risk after endoscopic papillo-sphincterotomy (EST). Recently somatostatin, which decreases both pancreatic flow rate and enzyme output, has been reported to prevent serum enzyme elevation after ERCP. The aim of this study was to evaluate in 54 patients, who underwent EST and received either somatostatin (i.v. 250 μg/hr for 26 hours) or isotonic saline as placebo, the effect of the hormone on enzymatic elevation. Eighteen hours after EST, somatostatin decreased the enzymatic elevation by about 30% in comparison with the placebo group; in patients with a history of recurrent pancreatitis the decrease was about 40%. However, these differences were not statistically significant. Severe pancreatic reaction occurred in 2 cases of the somatostatin group and in 5 cases of the control group. In conclusion our data suggest that the use of somatostatin shows a negligible variation in enzymatic rise in unselected patients, however, the hormone may be useful in patients with recurrent pancreatitis. However, when a papillary oedema is the probable cause of a marked reduction of pancreatic juice flow, the infusion of somatostatin seems to be only partially effective in preventing major complications.

Original languageEnglish
Pages (from-to)70-73
Number of pages4
JournalItalian Journal of Gastroenterology
Volume20
Issue number2
Publication statusPublished - 1988

Fingerprint

Endoscopic Sphincterotomy
Somatostatin
Pancreatitis
Hormones
Pancreatic Juice
Placebo Effect
Endoscopic Retrograde Cholangiopancreatography
Enzymes
Edema
Placebos
Control Groups
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic papillo-sphincterotomy : Prevention of pancreatic reaction by somatostatin. / Testoni, P.; Masci, E.; Bagnolo, F.; Tittobello, A.

In: Italian Journal of Gastroenterology, Vol. 20, No. 2, 1988, p. 70-73.

Research output: Contribution to journalArticle

@article{514cbc53f1194b678d6041da71e80b6c,
title = "Endoscopic papillo-sphincterotomy: Prevention of pancreatic reaction by somatostatin",
abstract = "Acute pancreatitis is widely considered as a harmful risk after endoscopic papillo-sphincterotomy (EST). Recently somatostatin, which decreases both pancreatic flow rate and enzyme output, has been reported to prevent serum enzyme elevation after ERCP. The aim of this study was to evaluate in 54 patients, who underwent EST and received either somatostatin (i.v. 250 μg/hr for 26 hours) or isotonic saline as placebo, the effect of the hormone on enzymatic elevation. Eighteen hours after EST, somatostatin decreased the enzymatic elevation by about 30{\%} in comparison with the placebo group; in patients with a history of recurrent pancreatitis the decrease was about 40{\%}. However, these differences were not statistically significant. Severe pancreatic reaction occurred in 2 cases of the somatostatin group and in 5 cases of the control group. In conclusion our data suggest that the use of somatostatin shows a negligible variation in enzymatic rise in unselected patients, however, the hormone may be useful in patients with recurrent pancreatitis. However, when a papillary oedema is the probable cause of a marked reduction of pancreatic juice flow, the infusion of somatostatin seems to be only partially effective in preventing major complications.",
author = "P. Testoni and E. Masci and F. Bagnolo and A. Tittobello",
year = "1988",
language = "English",
volume = "20",
pages = "70--73",
journal = "Italian Journal of Gastroenterology",
issn = "0392-0623",
publisher = "Piccin Editore",
number = "2",

}

TY - JOUR

T1 - Endoscopic papillo-sphincterotomy

T2 - Prevention of pancreatic reaction by somatostatin

AU - Testoni, P.

AU - Masci, E.

AU - Bagnolo, F.

AU - Tittobello, A.

PY - 1988

Y1 - 1988

N2 - Acute pancreatitis is widely considered as a harmful risk after endoscopic papillo-sphincterotomy (EST). Recently somatostatin, which decreases both pancreatic flow rate and enzyme output, has been reported to prevent serum enzyme elevation after ERCP. The aim of this study was to evaluate in 54 patients, who underwent EST and received either somatostatin (i.v. 250 μg/hr for 26 hours) or isotonic saline as placebo, the effect of the hormone on enzymatic elevation. Eighteen hours after EST, somatostatin decreased the enzymatic elevation by about 30% in comparison with the placebo group; in patients with a history of recurrent pancreatitis the decrease was about 40%. However, these differences were not statistically significant. Severe pancreatic reaction occurred in 2 cases of the somatostatin group and in 5 cases of the control group. In conclusion our data suggest that the use of somatostatin shows a negligible variation in enzymatic rise in unselected patients, however, the hormone may be useful in patients with recurrent pancreatitis. However, when a papillary oedema is the probable cause of a marked reduction of pancreatic juice flow, the infusion of somatostatin seems to be only partially effective in preventing major complications.

AB - Acute pancreatitis is widely considered as a harmful risk after endoscopic papillo-sphincterotomy (EST). Recently somatostatin, which decreases both pancreatic flow rate and enzyme output, has been reported to prevent serum enzyme elevation after ERCP. The aim of this study was to evaluate in 54 patients, who underwent EST and received either somatostatin (i.v. 250 μg/hr for 26 hours) or isotonic saline as placebo, the effect of the hormone on enzymatic elevation. Eighteen hours after EST, somatostatin decreased the enzymatic elevation by about 30% in comparison with the placebo group; in patients with a history of recurrent pancreatitis the decrease was about 40%. However, these differences were not statistically significant. Severe pancreatic reaction occurred in 2 cases of the somatostatin group and in 5 cases of the control group. In conclusion our data suggest that the use of somatostatin shows a negligible variation in enzymatic rise in unselected patients, however, the hormone may be useful in patients with recurrent pancreatitis. However, when a papillary oedema is the probable cause of a marked reduction of pancreatic juice flow, the infusion of somatostatin seems to be only partially effective in preventing major complications.

UR - http://www.scopus.com/inward/record.url?scp=0023952417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023952417&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023952417

VL - 20

SP - 70

EP - 73

JO - Italian Journal of Gastroenterology

JF - Italian Journal of Gastroenterology

SN - 0392-0623

IS - 2

ER -